The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
JI

j.iyer

TL2 Moderator · Essen

Contributes reviews on supplier material. Based in Essen.

Joined 12 July 2025 · last posted 10d

93Posts here
0Topics
1Solutions
150Likes received
183Likes given
17Badges
52Days visited
445Posts read

Most-liked posts

  • Stability of BPC-157 in solution: what has been measured — one year on Replied, post #33 · Compounds › Repair & healing peptides · 6 Apr 2026 · 31 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
  • Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #73 · Access › Pricing · 27 Jan 2026 · 31 likes post #72 answers the question as asked. The question underneath it is different. Pharmacy acquisition cost: a pharmacy pays less than the patient pays, even at…
  • Requesting a page: what makes a good request Replied, post #59 · Documentation › Wiki requests · 16 Apr 2025 · 31 likes post #58 answers the question as asked. The question underneath it is different. Scope creep: if you think a page is attempting too much and should be split into…
  • When "no data" is the complete and final answer Replied, post #131 · Compounds › Other compounds · 28 Mar 2025 · 30 likes Picking up post #128: that is the part I would want checked first. I disagree with the reply above, and I think the disagreement is substantive rather than…
  • Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #121 · Access › International · 24 Mar 2025 · 30 likes Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when…
  • Retatrutide dose escalation in the published trials Replied, post #27 · Compounds › Retatrutide · 19 Mar 2025 · 29 likes post #26 answers the question as asked. The question underneath it is different. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple…

Where this member posts

CategoryPostsShare
Compounds1819%
Analytics1415%
Practice1011%
Sourcing910%
Evidence910%
Clinical55%

Badges earned, in order

BadgeTierGranted
Basic Userbronze14 Jul 2025
Welcomebronze14 Jul 2025
Read the Guidelinesbronze15 Jul 2025
First Replybronze16 Jul 2025
First Quotebronze23 Jul 2025
Asked Wellbronze2 Aug 2025
First Linkbronze9 Aug 2025
First Tagbronze15 Aug 2025
Memberbronze27 Aug 2025
Sourcedbronze1 Oct 2025
First Solutionbronze2 Oct 2025
Readerbronze10 Oct 2025
Editorbronze15 Nov 2025
Nice Postbronze3 Jan 2026
De-escalatorgold14 Feb 2026
Good Postsilver23 Mar 2026
Anniversarysilver12 Jul 2026